Valuation: Cerenis Therapeutics

Market Cap 72M 82.11M 66.37M 62.13M 117M 7.75B 119M 798M 309M 3.83B 308M 302M 13.27B P/E 2026 *
-4.39x
P/E 2027 * -6.89x
Enterprise Value 77.8M 88.73M 71.71M 67.14M 126M 8.37B 129M 862M 334M 4.14B 333M 326M 14.34B EV / Sales 2026 *
16.7x
EV / Sales 2027 * 5.5x
Free-Float
82.43%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 2019-09-05
Director of Finance/CFO - -
Chief Operating Officer - 2005-12-31
Director TitleAgeSince
Director/Board Member 49 2019-09-05
Director/Board Member 52 2010-07-19
Director/Board Member 76 2015-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 82.11M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.10%+4.78%+42.39%+130.58% 25.14B
Weighted average by Cap. +0.26%+5.13%+48.50%+122.68%

Financials

2026 *2027 *
Net sales 4.66M 5.31M 4.3M 4.02M 7.54M 501M 7.7M 51.62M 19.98M 248M 19.96M 19.52M 859M 14.72M 16.78M 13.57M 12.7M 23.82M 1.58B 24.31M 163M 63.09M 783M 63.03M 61.65M 2.71B
Net income -19.83M -22.61M -18.28M -17.11M -32.08M -2.13B -32.75M -220M -85M -1.05B -84.91M -83.05M -3.66B -12.92M -14.74M -11.91M -11.15M -20.91M -1.39B -21.34M -143M -55.4M -687M -55.34M -54.13M -2.38B
Net Debt 5.8M 6.61M 5.35M 5.01M 9.39M 624M 9.58M 64.26M 24.86M 308M 24.84M 24.3M 1.07B 9M 10.26M 8.3M 7.77M 14.56M 968M 14.87M 99.71M 38.58M 479M 38.54M 37.7M 1.66B
Logo Cerenis Therapeutics
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.040EUR
Average target price
10.50EUR
Spread / Average Target
+414.71%

Annual profits - Rate of surprise